Previous close | 6.50 |
Open | 6.50 |
Bid | 7.00 |
Ask | 9.20 |
Strike | 3.00 |
Expiry date | 2024-01-19 |
Day's range | 6.50 - 6.50 |
Contract range | N/A |
Volume | |
Open interest | 17 |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.